Aplidin (plitidepsin) is a novel marine-derived antitumor agent presently undergoing phase II clinical trials in hematological malignancies and solid tumors. Lack of bone marrow toxicity has encouraged further development of this drug for treatment of leukemia and lymphoma. Multiple signaling pathways have been shown to be involved in Aplidin-induced apoptosis and cell cycle arrest in G 1 and G 2 phase. However, the exact mechanism(s) of Aplidin action remains to be elucidated. Here we demonstrate that mitochondria-associated or -localized processes are the potential cellular targets of Aplidin. Whole genome gene-expression profiling (GEP) revealed that fatty acid metabolism, sterol biosynthesis and energy metabolism, including the tricarboxylic acid cycle and ATP synthesis are affected by Aplidin treatment. Moreover, mutant MOLT-4, human leukemia cells lacking functional mitochondria, were found to be resistant to Aplidin. Cytosine arabinoside (araC), which also generates oxidative stress but does not affect the ATP pool, showed synergism with Aplidin in our leukemia and lymphoma models in vitro and in vivo. These studies provide new insights into the mechanism of action of Aplidin. The efficacy of the combination of Aplidin and araC is currently being evaluated in clinical phase I/II program for the treatment of patients with relapsed leukemia and high-grade lymphoma.
Introduction
Aplidin (plitidepsin) is a cyclic depsipeptide originally isolated from the marine tunicate Aplidium albicans and is now currently chemically synthesized. In phase I studies, the main side effects noted were myalgia and muscle weakness, prevented by administration of L-carnitine. 1 Bone marrow toxicity was not dose limiting. 2 Phase II clinical studies are being carried out in solid and hematologic tumors with preliminary evidence of activity in advanced melanoma and multiple myeloma. 3 Aplidin has recently been granted orphan drug designation for the treatment of acute lymphoblastic leukemia and multiple myeloma by the European Medicines Agency and Food and Drug Administration. Despite active investigation, the exact mode of Aplidin action remains to be elucidated. Aplidin has been shown to cause apoptosis in various cancer cell lines and in activated T cells at nanomolar concentrations with much less of an effect on normal hematopoiesis. [4] [5] [6] Aplidin-induced apoptosis was shown to be mediated through activation and clustering of death receptors, FasL and downstream-signaling molecules, into lipid rafts. 7 Multiple signaling pathways have been shown to be involved in Aplidin apoptotic action for example, p38, MAPK, EGFR, protein kinase C, protein tyrosine phosphatase and JNK. 5, [8] [9] [10] These effects are dependent on the depletion of reduced glutathione, and point to the important role of oxidative stress in Aplidin mechanism of action. 9, 11, 12 Importantly, several studies have shown that Aplidin lacks cross-resistance with the currently used cytotoxic drugs. 13, 14 This encouraged us to undertake a systematic study of drug combinations with Aplidin, for possible use in hematological malignancies and to examine the mechanisms involved in cell kill produced by this combination.
Materials and methods

Cell culture
CCRF-CEM, a human T-lymphoblastoid cell line, SKI-DLCL, a human diffuse large cell lymphoma cell line and K562, a human erythromyeloblastic leukemia cell line were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin under standard cell culture conditions. The MOLT-4 human T-cell lymphoblastic leukemia cell line and a subline deficient in mitochondrial DNA content, MOLT-4r1 (subline deficient in mitochondrial DNA content), were cultured as described previously. 15 
Cytotoxicity assays
Cytotoxicity of Aplidin (PharmaMar, Spain), doxorubicin and methotrexate, mitoxantrone, methylprednisolone, vinblastine, cytarabine (araC; Sigma, St Louis, MO, USA), was assayed following 4 days exposure (2.5 Â 10 4 cells ml
À1
) using XTT or MTS reagents (Sigma) according to standard protocols.
In vitro combination studies SKI-DLCL, K-562 and CCRF-CEM cell lines were selected for these studies. Aplidin was combined with methotrexate, doxorubicin, mitoxantrone, methylprednisolone, vinblastine and cytarabine at a fixed ratio of doses that corresponded to 0.125, 0.25, 0. 
Cell cycle analysis
Analysis of cell cycle effects induced by Aplidin alone and in combination with araC was performed according to the protocol described by Darzynkiewicz et al. 17 Cells were analyzed by flow cytometry (FACS Calibur, Becton Dickinson, Franklin Lakes, NJ, USA). Data were analyzed using ModFit LT version 3.0 software (Verity Software House Inc., Topsham, ME, USA).
Gene-expression profiling
Total RNA was isolated from SKI-DLCL cells or tumors following treatment and gene-expression profiling (GEP) was performed using cDNA microarray technology at the CINJ Core Expression Array Facility (CINJ, New Brunswick, NJ, USA). Affymetrix chip HG U133A-2 was used. A list of genes whose expression was significantly changed (X1.5-fold, data transformed to log to the base of 2, log, and Pp0.05 from unpaired t-test) was generated. Z-score of gene ontology (GO) terms or biological pathways was used to assess biological significance of observed changes in gene expression. 18, 19 Data have been deposited in the Gene Expression Omnibus (GEO) repository and is publicly available under the accession number GSE5681. Mitochondrial membrane potential and ROS production A DePsipher kit (R&D System, Minneapolis, MN, USA) was used to detect mitochondrial membrane potential changes (c m ) after treatment with Aplidin alone or in combination with araC. Derivative of reduced fluorescein (H2DCFDA; Molecular Probes, Invitrogen, Carlsbad, CA, USA) was used as an indicator of reactive oxygen species (ROS). Experiments were performed according to the manufacturer's protocol. Valinomycin (100 nM) or hydrogen peroxide (10 mM) was used as a positive control.
Reverse transcription -PCR
FL-1 and FL-2 fluorescence were recorded using flow cytometry (FACSCalibur, Becton Dickinson).
Cellular ATP level
The Cell Titer-Glo (Promega, Madison, WI, USA) luminescencebased assay was used to quantitate the cellular ATP concentration. Oligomycin was used as a positive control. Experiments were performed according to the manufacturer's protocol. Luminescence was recorded with a luminometer TD-20-20 (Turner Design, DL Ready).
Results and discussion
In vitro cytotoxic effects of drug combinations with Aplidin
Our in vitro screen of Aplidin in combination with various drugs for possible use in hematological malignances showed strong synergism with araC in the CCRF-CEM cell line (CI ¼ 0.469; Figure 1a ), the SKI-DLCL cell line (CI ¼ 0.306; Figure 1b ) and in the K562 cell line (CI ¼ 0.487; data not shown). Aplidin was also found to potentiate the cytotoxic effect of other drugs, including methylprednisolone, doxorubicin and mitoxantrone depending upon cell line tested (Supplementary Table 1 ). As araC was found to be synergistic in combination with Aplidin in all three cell lines studied and is widely used in the treatment of leukemia and lymphoma, this combination was chosen for further evaluation in human xenograft models.
Aplidin potentiates the antitumor effect of araC in vivo
Addition of low-dose Aplidin to araC resulted in significant reduction in tumor size in CCRF-CEM and SKI-DLCL xenograft models. As visualized in Figure 1c , there was significant delay in CCRF-CEM tumor progression on day 5 after the treatment with only a single injection of 0.6 mg kg À1 Aplidin in combination with 50 mg kg À1 araC (Pp0.05) as compared to either drug alone and the effect was still maintained on day 8. A similar effect was observed with the SKI-DLCL tumor as shown in Figure 1d . No other toxic side effects besides a transient 15% weight loss were noted in the group of animals treated with Aplidin at 0.6 mg kg À1 . Presumably, more dramatic effects on tumor cell growth would be obtained with additional doses of these drugs.
Aplidin enhances araC-induced cell death
Consistent with in vitro and in vivo synergism studies, we observed that addition of araC to Aplidin significantly increased the number of cells with sub-G 1 DNA content as summarized in Table 1 
Gene-expression profiling of SKI-DLCL cells
To obtain a better insight into the mode of action of Aplidin as well as its contribution to the synergistic combination with araC, GEP was carried out on the SKI-DLCL cells treated for 24 h with IC 50 doses of Aplidin alone (3 nM), araC alone (20 nM) or the combination (5 nM araC þ 1.5 nM Aplidin). Doses of the drugs were chosen based on the 4-day cytotoxicity assay, and less than 10% cell death was observed at the 24 h time point for drugs alone. Hence, preapoptotic changes in GEP could be observed. Clustering of biological triplicates for each treatment revealed that Aplidin invokes similar changes in gene expression as a single agent as well as in combination with araC ( Figure 2a) .
A total of 905 genes were differentially expressed after treatment with Aplidin alone. The biological process ontologies associated with the differentially expressed genes were examined using a z-score report. 19 Changes in cellular metabolism, ) and araC alone (50 or 100 mg kg
À1
) or the combination of Aplidin and araC were administered to the animals when tumors were palpable (day 0). Aplidin in combination with araC R Humeniuk et al RNA and DNA metabolism, stress response and immune response and, in particular, transport mRNAs were overrepresented for the upregulated genes. Negative regulation of transcription, including RNA pol III promoter-mediated, and negative regulation of progression through cell cycle mRNAs were also found to be affected by Aplidin treatment. Among the genes that decreased in expression, the most significant one were those associated with lipid metabolism, sterol biosynthesis and especially cholesterol biosynthesis exhibiting the highest z-score. Genes involved in protein modification, folding, cell surface receptor signaling as well as synthesis of ATP and ion homeostasis were also affected by Aplidin treatment. To our knowledge, this is the first whole genome GEP analysis reported, aiming to characterize mechanism of action of Aplidin. Our results suggest that Aplidin has a pleiotropic effect on cells (Figure 2b ). The full list of the GO terms with corresponding z-score for up and downregulated genes can be found in Supplementary Table 2 . Cellular metabolism seems to be a primary target of Aplidin as it is affected at all levels and results in disruption of cell homeostasis and a stress response. These data are consistent with previous observations that Aplidin is not selective for rapidly dividing cells and blocks cells in G 1 phase of the cell cycle. 6 Interestingly, we observed that many of the metabolic processes targeted by Aplidin are either localized to 
Gene-expression profiling of SKI-DLCL lymphoma
To confirm whether similar genomic effect of Aplidin and araC combination observed in cultured SKI-DLCL cells occurs in vivo, additional GEP was carried out. SKI-DLCL tumors were harvested from animals treated with 0.4 mg kg À1 Aplidin and 100 mg kg À1 araC; as compared to control untreated SKI-DLCL tumor, 613 genes were differentially expressed. Pathway analysis revealed that the citrate cycle (TCA cycle), cell cycle, MAPK signaling and WNT signaling were significantly affected (Pp0.05) by the treatment with the combination (Figure 2c) . Interestingly, all genes that are crucial regulators of the TCA cycle including isocitrate dehydrogenase, oxoglutarate dehydrogenase, cis-aconitase and succinate-CoA ligase were found to be downregulated. This suggested that energy metabolism is affected in agreement with results from our in vitro GEP analysis. Key regulators of the cell cycle, for example, Mdm2, S-phase kinase-associated protein 2 (p45) and E2F transcription factor 5, were found to be downregulated, while cyclin-dependent kinase inhibitor 2D (p19) and cyclin-dependent kinase inhibitor 2C (p18) were found to be upregulated. Signaling through the MAPK pathway was found to be highly affected by the treatment as 31 genes from this pathway were differentially expressed. A full list of genes from each affected pathway is shown in Supplementary Table 3 . Results were validated using RT-PCR as shown in Supplementary Table 4 .
Time-course gene-expression profiling analysis
To narrow the number of changes observed following the Aplidin treatment and to identify processes that are upstream of this drug's pleiotropic effect on the cell, additional microarray experiments were carried out. SKI-DLCL cells were treated with low-dose (0.5 nM) Aplidin for 15 min, 1 or 24 h. Comparative analysis showed that, on average, 250 genes changed its expression following the treatments as soon as 15 min following Aplidin addition. Expression of important regulators of energy metabolism, fatty acid metabolism, transcription as well as protein modification, trafficking and folding, were primarily affected. A list of genes that showed 4-fold or greater change in gene expression is shown in Supplementary Table 5 .
Of interest, pyruvate dehydrogenase kinase that inhibits conversion of pyruvate into acetyl-CoA was 10-fold upregulated after 15 min and lactate dehydrogenase was 30-fold upregulated after 24 h exposure to Aplidin. Fatty acid-binding protein 7, suggested recently in literature to be a potential new target for cancer, was downregulated 25-fold after 15 min following drug exposure as well as a-methylacyl-CoA racemase (5-fold), a mitochondrial enzyme responsible for the b-oxidation of branched fatty acids. 20 Glycoprotein synthesis was affected by downregulation of 1,4-galactosyltransferase and N-acetylgalactosaminyltransferase 8 after 15 min, and lasted up to 24 h. Transcription was affected by downregulation of SET domain containing 1A (10-fold), histone methyltransferase, primarily responsible for H3Lys9 methylation, RNA polymerase II polypeptide A (5-fold), mediator of RNA polymerase II transcription (4-fold) and ADP-ribosyltransferase 3 (10-fold) following 15 min or 1 h exposure to Aplidin. In summary, Aplidin affects energy metabolism, presumably by inhibiting the TCA cycle, and fatty acid metabolism. Effect of Aplidin on regulation of transcription may explain the large number of changes observed even with short-term exposures and needs to be explored further.
Effect of Aplidin on mitochondrial functions
Analysis of gene expression following Aplidin treatment pointed to mitochondria as a possible target of Aplidin. To address this further, we examined the effect of Aplidin on c m , ROS production and ATP synthesis; processes often influenced by cytotoxic drugs. Following Aplidin treatment, no change in c m was observed (Figure 3a) . Interestingly, treatment with even low doses of araC resulted in a rapid and sustained decrease of c m . The effect of araC on depolarization of the mitochondrial membrane was also seen in the combination with Aplidin. Our data suggest that unlike araC, Aplidin does not activate the mitochondrial apoptotic pathway. Aplidin has been previously reported to induce apoptosis in vitro mainly through Fasreceptor activation. 5, 7 Next, we examined the effect of Aplidin and araC on ROS production. Both Aplidin and araC treatments alone and in combination resulted in significant induction of ROS (Figure 3b ). It has been reported recently that the source of Aplidin-induced Aplidin in combination with araC R Humeniuk et al ROS is the electron transport chain since rotenone, but not other known inhibitors, selectively blocks ROS production by Aplidin. 11 The increase in mitochondrial membrane potential following Aplidin treatment could be attributed to ROS production and is a sign of mitochondrial swelling and disruption of the outer membrane. 21 However, ROS generated by araC is probably of a different source as indicated by antioxidants used to prevent araC toxicity. 22 Finally, we examined ATP levels following Aplidin treatment. Interestingly, we observed that Aplidin significantly decreases ATP levels in a dose-and time-dependent manner as shown in Table 2 . An equal number of cells was taken to quantitate ATP content and reduction in ATP levels is expressed as the percentage of ATP levels in untreated cells. AraC alone did not have any effect on cellular ATP levels during the 24-hincubation time. Several genes involved in electron-coupled proton transport, including mitochondrial ATP synthase, were downregulated in our GEP of SKI-DLCL cells and the TCA cycle was highly affected in GEP of SKI-DLCL tumor. Aplidin, alone and in combination with araC, resulted in a similar decrease of ATP pool. Many of the observed changes in GEP could be mediated by lack of ATP in the cell as a majority of the metabolic processes and protein kinase-mediated signaling depend on ATP. In addition many transporters, including ion transporters require ATP. Aplidin-mediated decreases in the cellular ATP pool has not been reported before and may be an important missing piece of the puzzle of the mode of action of Aplidin. However, the exact mechanism of ATP synthesis inhibition or depletion remains to be elucidated.
Cells lacking functional mitochondria are resistant to Aplidin
In addition to ATP synthesis, mitochondria are the site of steroid hormone synthesis, the urea cycle, lipid metabolism, interconversion of amino acids, glucose sensing and calcium homeostasis, which in turn may affect numerous cell-signaling pathways. [23] [24] [25] Consistent with our GEP results, we observed that MOLT-4r1 cells that lack functional mitochondria were threefold more resistant to Aplidin as well as to its combination with araC (Figures 4a and b) . In contrast, no significant difference in sensitivity to other anticancer drugs namely vinblastine or methotrexate, was observed in MOLT-4r1 cells as compared to the parental MOLT-4 cells, suggesting that apoptosis induction through the mitochondrial pathway is intact in MOLT-4r1 (Figures 4c and d) . It remains to be determined if and which mitochondria-localized processes could be used as a useful marker for predicting Aplidin sensitivity.
